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Abbreviations and glossary 
 
ABMR  antibody mediated rejection 
AR  acute rejection 
AUC  area under the ROC curve 
ATG  anti-thymocyte globuline 
ATS  American Transplantation Society 
BKVN  BK-virus nephropathy 
BTS  British Transplantation Society 
CV.AUC cross-validated AUC 
eGFR  estimated glomerular filtration rate 
ESOT  European Society of Organ Transplantation  
GLMM  generalised linear mixed-effects models 
HLA   Human Leucocyte Antigen 
IS  immunosuppression 
KTR  kidney transplant recipients 
Parsimonious The answer that makes the fewest assumptions; in this manuscript 
the smallest set of genes showing a satisfactory predictive 
performance  
PB   peripheral blood 
ROC  receiver operator characteristics curve 
RT-qPCR Real time – quantitative Polymerase Chain Reaction 
SCr  Serum Creatinine 
TCMR  T cell mediated Rejection 
TTS  The Transplantation Society 
 
  




Research in Context 
 
Evidence Before the Study 
Patients with kidney transplants are at significant risk of transplant failure, 
risking return to renal replacement therapy or having another kidney transplant. 
Apart from HLA variants mismatches, specific genetic features that are 
responsible for kidney transplant failure have not been identified thus far.  
It remains unknown which of the large number of patients with kidney 
transplants will get worsening of their kidney function with time. Molecular 
analysis of peripheral samples from transplant recipients potentially would 
allow surveillance of immune activation enabling earlier detection and treatment 
of rejection.  
Our literature search has been primarily focused on PubMed and Scopus 
searches and through information received in and around transplantation 
meetings (BTS, ATC, ESOT and TTS) where preliminary work of ours and other 
groups has been presented and discussed. 
Previous studies in kidney transplant recipients have identified a number of 
genes in blood and urine samples which correlate with acute rejection; many of 
which are involved in cytotoxic T lymphocyte function and cell trafficking. These 
include Granzyme B, Perforin, Fas-ligand, FoxP3 and CXCL10 and interleukins. 
However, single genes have lacked the sensitivity and specificity to translate 
early acute rejection detection into clinical practice. In urine, a three-gene 
signature has been found which was also able to predict the clinical episode by 
some weeks. In blood microarray studies have identified gene-sets capable of 
distinguishing acute rejection. These, however, have not been analysed in a serial 
fashion to allow for determination of their predictive value and they do not 
examine the effects of anti-rejection therapy. In cardiac transplantation a 
commercially available 11 gene set has been shown to reduce the need to 
perform biopsies and led to greater patient satisfaction. 
Most recently, the multi-centre AART study from the US has identified a 17 gene 
set in blood with an AUC of 0.94 and show a predictive value up to 3 months 
before detection by biopsy, but further clinical validation is still awaiting.  
 
Added Value of this Study 
This is the first European study to comprehensively analyse serial blood samples 
from renal transplant recipients. We collected samples from 450 consecutive 
adult recipients at regular intervals over their first year post-transplant. This has 
allowed us to perform both cross sectional and longitudinal analysis. Patients 
selected for the discovery phase all received a similar anti-rejection protocol. 
Importantly this included induction therapy with an IL-2R blocking antibody 
(Basiliximab) rather than a lymphocyte depleting antibody, the latter being more 
common practice in the US. Given that some of the genes are lymphocyte 
expressed, the induction agent might have a significant effect on lymphocyte 
gene expression, which we have observed. In longitudinal analysis we have 
demonstrated for the first time the significant intra patient variability over time 
and a relationship to changes in anti-rejection therapy. Here we describe a 
parsimonious (the one that makes the fewest assumptions) T cell mediated 
rejection (TCMR) signature using the expression of seven genes in peripheral 
blood. 




We have also been able to demonstrate the predictive value of our signature, 
with detection of acute rejection demonstrable up to two months before the 
clinical event. We have subsequently carried out validation in a separate cohort 
of patients. All in all the number of samples analysed throughout our study 
nearly doubles the numbers of samples used in the AART study, including 
therefore a more comprehensive longitudinal picture of the gene measurements. 
 
In order to assist the differential diagnosis with BK-virus nephropathy (BKVN), 
which has the same clinical presentation as T cell mediated rejection (TCMR), 
but requires the opposite therapy, namely immunosuppression reduction, we 
have additionally developed a six-gene signature of BKVN. Further, we have 
examined patients with alternative induction regimens. Patients treated with 
Rituximab showed similar gene-expression patterns to patients treated with 
Basiliximab, whilst patients receiving Alemtuzumab treatment showed both, 
high TCMR and high BKVN positivity. 
 
Implications of all the available evidence 
Information from gene expression in peripheral blood samples from transplant 
recipients could provide valuable information to clinicians for more personalised 
management and finally provide some information on the recipient’s immune 
status.  
Potential benefits include earlier detection and treatment of acute rejection as 
well as separation from other causes of graft dysfunction, something which the 
presently used non-invasive monitoring tool, namely serum creatinine is unable 
to do. It may also allow reduction of anti-rejection therapy in other patients, 
minimising side effects, that may further allow personalised precision medicine. 
A trial of these biomarkers for evaluation in clinical practice is now needed. 
We believe the potential of the analysis strategy we applied could be used in 
other biomarker signatures where longitudinal evaluation is critical and this 
warrants the scrutiny by the wider readership. 
  







Acute T-cell mediated rejection (TCMR) is usually indicated by alteration in 
serum-creatinine measurements when considerable transplant damage has 
already occurred. There is, therefore, a need for non-invasive early detection of 




We examined the RT-qPCR expression of 22 literature-based genes in peripheral 
blood samples from 248 patients in the Kidney Allograft Immune Biomarkers of 
Rejection Episodes (KALIBRE) study. To account for post-transplantation 
changes unrelated to rejection, we generated time-adjusted gene-expression 
residuals from linear mixed-effects models in stable patients. To select genes, we 
used penalised logistic regression based on 27 stable patients and 27 rejectors 
with biopsy-proven T-cell-mediated rejection, fulfilling strict inclusion/exclusion 
criteria. We validated this signature in i) an independent group of stable patients 
and patients with concomitant T-cell and antibody-mediated-rejection, ii) 
patients from an independent study, iii) cross-sectional pre-biopsy samples from 
non-rejectors and iv) longitudinal follow-up samples covering the first post-
transplant year from rejectors, non-rejectors and stable patients. 
 
Findings 
A parsimonious TCMR-signature (IFNG, IP-10, ITGA4, MARCH8, RORc, SEMA7A, 
WDR40A) showed cross-validated area-under-ROC curve 0·84 (0·77-0·88) 
(median, 2·5th-97·5th centile of fifty cross-validation cycles), sensitivity 0·67 
(0·59-0·74) and specificity 0·85 (0·75-0·89). The estimated probability of TCMR 
increased seven weeks prior to the diagnostic biopsy and decreased after 
treatment. Gene expression in all patients showed pronounced variability, with 
up to 24% of the longitudinal samples in stable patients being TCMR-signature 
positive. In patients with borderline changes, up to 40% of pre-biopsy samples 
were TCMR-signature positive. 
 
Interpretation 
Molecular marker alterations in blood emerge well ahead of the time of clinically 
overt TCMR. Monitoring a TCMR-signature in peripheral blood could unravel T-
cell-related pro-inflammatory activity and hidden immunological processes. This 
additional information could support clinical management decisions in cases of 
patients with stable but poor kidney function or with inconclusive biopsy results. 
 
Funding: 
EU: FP7-HEALTH-2012-INNOVATION-1 (project-305147: BIO-DrIM) and FP7 
grant agreement no HEALTH-F5–2010–260687. 
Medical Research Council: G0600698, MR/J006742/1; G0802068; 
MR/K002996/1 and G0801537/ID: 88245. 
NIHR Biomedical Research Centre at Guy’s and St Thomas’ and King’s College 
London.  
  





Kidney transplantation remains the optimal treatment for patients with end-
stage kidney disease but requires life-long anti-rejection therapy, which is a 
major contributor to morbidity and mortality in kidney transplant recipients 
(KTRs). Balancing the level of immune suppression in each recipient remains a 
major challenge, and occurs in a reactive fashion in response to clinical events. 
Monitoring of allograft function presently relies on serum creatinine (SCr) 
values. SCr is not a sensitive marker, as it often changes only after a considerable 
graft damage, and is not a specific marker either, as it can be affected by several 
factors other than rejection and patients further require a percutaneous biopsy 
to diagnose the cause of transplant dysfunction. A biopsy, however, is an invasive 
procedure carrying risks and, being prone to sampling error, could potentially 
fail to adequately uncover the cause of transplant dysfunction, with many cases 
reported as “borderline suspicious for acute cellular rejection”.1 Further, a 
biopsy is usually carried out only when there is clear evidence of transplant 
dysfunction, at which point irreversible tissue damage may already have 
occurred. Studies from centres carrying out routine biopsies at defined time-
intervals have also demonstrated a significant amount (10-30%) of rejection in 
the presence of unchanged renal function. 
As molecular events precede the development of the immune response, they 
provide an ideal opportunity to detect host responses before significant damage 
to the transplant has occurred. While such changes can be detected in tissue 
from biopsies, the ability to detect a signal in non-invasive samples such as 
peripheral blood and urine has the added practical advantage of allowing 
collection of serial samples. Monitoring of gene-expression signatures in 
peripheral blood and urine samples offers the opportunity for surveillance of the 
recipient immune system and earlier detection of acute rejection (AR), of diverse 
aetiology. 
In fact, previous studies have identified in both, blood and urine, a number of 
mRNAs associated with AR.7 These have included molecules associated with 
cytotoxic lymphocyte function, such as Perforin, Granzyme B, Fas-ligand and 
FoxP3. Single genes, however, lack the sensitivity and specificity to translate into 
clinical practice, and could hardly capture the complexity of the rejection 
process.  Technological advances now allow reliable and cost-effective analysis 
of multiple genes in a single sample. In urine, a three-gene signature of AR has 
been described with an area under the curve (AUC) of 0.85 (sensitivity 79%, 
specificity 78%) and an increase in gene expression detected up to 20 days 
before a clinically-evident AR.2 In cardiac transplantation, the use of an 11-gene 
panel has been studied and compared against the standard approach of routine 
biopsies. Use of the panel resulted in fewer performed biopsies and greater 
patient satisfaction.3 
A critical differential diagnosis of AR is polyoma BK-virus nephropathy (BKVN).4 
This is manifested, similarly to AR, with graft dysfunction and mononuclear 
infiltrates in biopsy samples but, unlike AR, is the result of immunosuppression 
(IS) that maybe excessive for the requirements of the individual. Importantly, the 
treatment of BKVN (reduction of IS medication) is opposite to that of AR and the 
definitive diagnosis relies on a specialised immunohistochemistry staining of a 
biopsy sample.5 While a reasonable inter-laboratory agreement in detection of 
BKVN was found in a Banff quality assurance initiative,6 focal lesions may 




become responsible for a false-negative biopsy. Taking all evidence into account, 
there is still a need for an alternative non-invasive biomarker of clinically-
relevant BKVN. 
In this study we have performed a comprehensive analysis in serial peripheral 
blood samples from KTRs of a set of 22 candidate genes with reported 
association with T-cell-mediated rejection (TCMR) in the literature 
(Supplementary Table S1). We have identified a robust gene-expression 
signature for TCMR and have examined longitudinally gene expression and the 
effect of different anti-rejection therapies. We subsequently tested the 
performance of our signature in a validation set of patients and an independent 
cohort.  
This information could finally provide clinicians with some insight into the status 
of a recipient’s immune system and be used as part of the complex clinical 
management process, when deciding whether or not to perform a biopsy and in 






Blood samples were collected serially from 455 consecutive KTRs, transplanted 
at a single regional transplant centre (Guy’s Hospital) in the Kidney Allograft 
Immunological Biomarkers of Rejection (KALIBRE) study. Patients were 
followed up at three independent Renal units (Guy’s, King’s College, and Kent & 
Canterbury Hospitals). Samples were collected at 26 time-points during clinic 
visits over the first post-transplant year. A total of 1464 samples from 248 
patients were used in the study, including 66 patients with an episode of 
rejection (Supplementary Figure S1). Patient flow-chart is shown in Figure 1. 
All patients contributing to the signature-development training dataset 
(inclusion/exclusion criteria listed in Table 1) had received treatment according 
to an anti-rejection protocol including Basiliximab induction followed by 
maintenance therapy with Tacrolimus or Cyclosporine, Mycophenolate Mofetil 
and Prednisolone. Histological criteria followed the Banff ’09 classification,8 as 
this was the most updated version at the beginning of recruitment and it was 
maintained for consistency throughout the study. Patients were categorised as 
Stable (when their SCr levels were within 20% of baseline), antibody-mediated 
rejection (category 2, ABMR); T-cell-mediated rejection (category 4, TCMR); 
mixed rejection (histological features of both, ABMR and TCMR) (mixed); and BK 
virus nephropathy (BKNV). Patient demographics are summarised in Table 2a 
and their immunological risk stratification in Table 2b. External validation KTRs 
(nine rejectors, 15 non-rejectors, one BKVN) were provided by patients from 
Guy’s Hospital (UK) participating in the EMPIRIKAL trial9 (EUdraCT: 2011-
000958-30). We also included healthy controls (n=14), previously recruited as 
part of the GAMBIT study.10  
 
Ethics statement 
Approval from research ethics committees was obtained for all included studies: 
KALIBRE - Research Ethics No: 09/H0711/58; GAMBIT - Research Ethics No: 




09/H0713/12; EMPIRIKAL - Research Ethics No: 12/LO/1334. Written informed 
consent was obtained from all patients participating in each of those studies. 
 
Gene-expression analysis 
Peripheral blood was collected into Tempus™ Blood RNA Tubes (Life-
Technologies) and stored at -20oC. RNA isolation, cDNA synthesis and RT-qPCR 
conditions have been previously described in detail.10 We analysed 22 genes 
(Supplementary Table S2a-b). Relative gene expression values were calculated 
with the –∆Ct method, detecting the difference with hypoxanthine-
phosphoribosyltransferase (HPRT) as a house-keeping gene. An in-house quality 
control (QC) sample was included in every analytical batch, which showed very 
low between-run variability (coefficients of variation between 0·19% and 
1·09%, median 0·48%). Missing data was minimal (below 0·5%). 
 
Sample size 
Sample size for signature development was determined by patient availability. 
We included all recipients with T-cell-mediated rejection (TCMR) (n=27) and 
BKVN (n=7) fulfilling the inclusion/exclusion criteria (Table 1) and the same 
number of stable patients (n=27), matched to rejectors in age, sex, and donor 
type, with no biopsy performed and <20% SCr change after achieving baseline. 
Power calculation (using an exponential approximation to estimate AUC 
variance),11, showed that with 27 patients in each group, we could estimate a 
95% confidence interval with half-width 0·103 for an expected AUC of 0·85 and 
with better precision for higher AUC. 
 
Statistical analysis 
Statistical analysis was performed in R version 3.2.2.12 Non-parametric 
Wilcoxon-Mann-Whitney test was used for univariate class comparisons. 
Association between continuous variables was evaluated with Spearman 
correlation coefficient (r). Outliers were recoded to the next highest or lowest 
value for multivariable analysis. Missing gene-expression data were imputed 
with K-nearest neighbour for microarrays (impute package).13 Missing values 
were first imputed in a 22-gene matrix of longitudinal samples, including 
samples collected from day 4 to rejection in training rejectors (n=201) and 
between days 4 and 400 post-transplantation from stable patients (n=335, 
Supplementary Fig. S2). The complete training matrix was then used to impute 
missing gene-expression for test samples, one at a time and based only on the 
genes included in the examined model. 
To account for the dependency of samples from the same patient, serial samples 
were analysed with generalised linear-mixed effects models (GLMM) with a 
linear, quadratic and cubic term for the fixed and random effects of time.  
To account for dependency of gene-expression on time post-transplantation we 
generated time-adjusted gene-expression values, individually for each gene, as 
the residuals of cubic GLMM linear regression models with the –∆Ct values, 
based on serial samples from training stable patients (residuals for all other 
patients were generated using these training models). 
To develop a TCMR signature, we compared samples from TCMR rejectors (a 
single pre-rejection sample per patient, zero to nine, median: three days pre-




biopsy) and stable patients (serial samples of ten to 20, median: 12 per patient; 
total: 335, summarised with the median time-adjusted expression for each gene 
per patient). To develop a gene-expression signature of BKVN, we compared 
BKVN-positive patients (a single sample per patient, within seven (median zero) 
days of a diagnostic biopsy) with the combined group of TCMR rejectors and 
stable patients, to secure simultaneous discrimination from non-BKVN KTRs. 
 
To select a parsimonious gene-expression signature, i.e. the smallest set of genes 
showing a satisfactory predictive performance, we used penalised logistic 
regression with an elastic net penalty14 (glmnet package12). Elastic net enables 
gene selection by shrinking the regression coefficients of genes statistically non-
informative for discrimination and, hence, retaining only genes, which are 
statistically-important based on the data used in the model. For the penalty 
parameters, we selected the alpha (tested in increments of 0·1), which enabled 
retaining a satisfactory  model performance with the minimum number of strong 
predictors (i.e. those gene remaining without shrinkage at high values of alpha). 
The penalty parameter lambda was optimised as the median of 200 seven-fold 
cross-validation repeats of the cv.glmnet function. The final signature models 
were based on imputation, time-adjustment and elastic net regression 
performed in the complete signature-development dataset. 
 
To evaluate model performance, we used the AUC (95% De Long confidence 
interval) and calculated sensitivity and specificity for a cut-off that optimised 
both for TCMR and specificity only for BKVN, but retaining sensitivity above 0·70 
(pROC package).15  
To compare the pre- and post-rejection trajectories of the probability of TCMR in 
rejectors and non-rejectors, we used GLMM linear regression with an interaction 
term for group and time. We used as outcome the predicted log-odds of rejection, 
which, unlike probability, has an unrestricted continuous scale. As a reference 
time-point in rejectors we used the day of the diagnostic biopsy. In non-rejectors, 
after demonstrating the time-independence of the predicted probability of 
TCMR, we assigned a time with respect to the reference point at random. This 
ensured that the distribution of samples from non-rejectors matched the pattern 
of rejectors with respect to time post-transplantation (Supplementary Fig. S3). 
Samples contributing to signature development, i.e. the 27 pre-biopsy samples 
for patients with TCMR and the 335 samples from the training stable patients, 
were excluded from the longitudinal analysis. Although the remaining pre-
rejection samples from the 27 training rejectors were included in the imputation 
matrix, they did not contribute to elastic net regression (i.e. gene selection and 
regression coefficients) and, with a missingness below 0·5%, they would not 
have materially influenced signature development. 
 
Validation strategy 
It should primarily be noted, that obtaining the 22 initial genes from literature 
reports and not from a statistical analysis of microarrays performed in our own 
dataset meant that our study provided a validation dataset for already published 
findings.  
Further, to evaluate the performance of the selected parsimonious gene-
expression signature with unseen data, we used the following approaches:  




First, we used cross-validation within the signature-development dataset. In the 
cross-validation cycles all steps of signature development (including the linear 
regression models generating time-adjusted residuals,  the imputation of missing 
data and the elastic net regression models performing the inherent to them gene 
selection (starting from the complete list of 22 genes for each model) and the 
required optimisation of the lambda parameter), were performed with the 
training subset. The left-out test subset was used solely for model validation (see 
Note 1 in Supplementary Discussion for further details). A cross-validation AUC 
(CV.AUC) was determined for each of 50 repeats of seven-fold cross-validation 
cycles, along with sensitivity and specificity at the fixed cut-off determined as 
optimal for the final signature model. Model performance measures obtained in 
the 50 cross-validation cycles were summarised with median (2·5th – 97·5th 
centile). 
Second, we performed cross-sectional validation in unseen test patients, using 
mixed-type rejectors (with histological features of both, TCMR and antibody-
mediated rejection (ABMR)) and new (test) stable patients. We further examined 
samples collected prior to non-rejection biopsies with different histological 
categories, pre-rejection samples from patients with ABMR and from rejectors 
treated with alternative immunosuppression induction agents (Alemtuzumab 
and Rituximab), near-biopsy samples from patients with BKVN, and samples 
from healthy controls. 
Third, we performed validation in longitudinal samples. To test signature 
specificity we used the individual longitudinal samples from the new test stable 
patients and also from other unseen test non-rejectors with more compromised 
renal function (with or without a for-cause biopsy during the first post-
transplant year) and from non-rejectors with alternative immunosuppression 
induction (the median sample per patient participated in the cross-sectional 
validation). Specificity of the TCMR signature was further examined in 
longitudinal samples from BKVN patients. In addition, we compared serial 
samples from rejectors with the combined group of the non-rejectors and the 
new stable patients. Rejectors included independent test rejectors (with TCMR 
and mixed-type rejection) and only the pre and post rejection samples from the 
27 training rejectors with TCMR, which were unseen in the elastic net regression 
defining the signature model. 
Fourth, we performed external validation with samples from independent 
rejectors with TCMR features and non-rejectors from the EMPIRIKAL trial (a pre-
rejection sample for rejectors and longitudinal samples for non-rejectors). 
 
Data sharing 
 Research data will be made available through application to the Biobank 
"Transplantation, Immunology and Nephrology Tissue and Information Nexus" 
(TIN-TIN) based at King’s College London, London UK. Provisional Ethics Ref: 
17/LO/0220. 
 
Role of the funding sources 
The study sponsors had no involvement in the study design, the collection, 
analysis, and interpretation of data, in the writing of the report, and in the 
decision to submit the paper for publication. 
 






Examining gene expression in longitudinal samples of training stable patients 
demonstrated high within-patient variability and systematic trajectory changes 
over the first four months post-transplantation (Fig. 2a-b). The expression of 19 
of the 22 studied genes was significantly associated with time (Supplementary 
Table S3). After accounting for prednisolone dose, which is systematically 
reduced during the first post-transplant months (Supplementary Fig. S4), the 
association of gene-expression and time was retained, independently of 
prednisolone, for 10 of the 22 genes (Supplementary Table S3), whilst eight 
genes showed an association with prednisolone, independent of time. 
Consequently, we generated time-adjusted gene-expression levels (Fig. 2c-d) and 
used these in signature development. This ensured that differences between 
stable patients and rejectors were accounted for by rejection and not by time-
related post-transplantation changes. 
Using penalised logistic regression with elastic net penalty, we developed a 
parsimonious signature of TCMR, retaining seven genes with non-zero 
regression coefficients and, hence, referred to as a “seven-gene” signature 
(Supplementary Fig. S5/S6a/S7, Tables S4/S5), which showed improved 
predictive performance in cross-validation (CV.AUC 0·84 (0·77-0·88)) compared 
to the 22-gene model (Table 3, Fig. 3a). This suggests that many of the 22 
original genes contribute more variability and noise to the 22-gene model than 
information facilitation the discrimination and, therefore, they could not be 
validated in our dataset (Supplementary Figure S5). It should also be noted that 
a comparison with eGFR as a diagnostic parker is not appropriate, as SCr has 
been used as a selection criterion (see Note 2 in Supplementary Discussion). 
The TCMR signature showed excellent discrimination between mixed-type 
rejectors and new stable patients in cross-sectional validation samples that had 
similar distribution of immunological risk pre-transplant stratification (Table 2b, 
Fig. 3b) (AUC 0·90 (0·70 – 1·00)). In the external validation dataset from the 
EMPIRIKAL trial, seven out of the nine rejectors (78%) were TCMR-positive near 
the diagnostic biopsy (Fig. 3c). EMPIRIKAL non-rejectors had distinctly worse 
kidney function compared to KALIBRE stable patients (Fig. 3f-g vs 3h), with eight 
out of 15 patients requiring dialysis in the first two weeks post-transplantation. 
Nevertheless, a discrimination could be achieved from TCMR (AUC 0·77 (0·53 – 
1.00)). No discrimination could be achieved between TCMR and stable patients 
pre-transplantation (Fig. 3d) (AUC 0·57 (0·38 – 0·76)).  
Whilst BKVN patients had low eGFR, similar to that of rejectors (Fig. 3k), they 
were TCMR-negative or only weakly positive (Fig. 3e). Five out of ten mixed-type 
rejectors treated with a different induction agent were TCMR-positive near the 
diagnostic biopsy (Fig. 3e). Three of the five patients with features only of ABMR 
in the first biopsy diagnostic of AR were TCMR-positive, but the one with the 
highest probability of TCMR showed features of mixed-type rejection in a 
subsequent biopsy, performed eight days after the collection of the sample 
shown in Fig. 3e. 
Preceding a for-cause biopsy without features of AR, seven out of eight KTRs with 
normal histology were TCMR-negative, but more than 30% of the patients with 
histological features of borderline changes, chronic rejection or other non-




rejection alterations were TCMR-positive (Fig. 4a) and the predicted probability 
of TCMR was negatively correlated with eGFR (r=−0·40, p<0·0001)(Fig. 4c). Half 
of the 14 healthy controls were TCMR-positive.  
In longitudinal samples from the stable patients used for signature development, 
the average predicted probability of TCMR remained constant with time post-
transplantation, below the cut-off, and was not influenced by adjustment for 
prednisolone dose (Supplementary Fig. S8a). The probability of TCMR also 
remained below the cut-off for validation stable patients and non-rejectors 
(Supplementary Fig. S8b). Further, over the first post-transplant year, the TCMR 
signature demonstrated very good specificity (above 70%) in stable patients, 
non-rejectors, and BKVN patients (Table 4). Rituximab induction showed 
similarity to Basiliximab induction (Fig. 4b), but TCMR-signature positivity was 
higher following Alemtuzumab induction (71%), despite the comparable eGFR in 
alternative induction groups (Fig. 4d). Similarly, in non-rejectors of the 
EMPIRIKAL trial a larger proportion of the longitudinal samples were TCMR-
positive (44%), with ten out of the 14 samples from the first post-transplant 
week being TCMR-positive. 
In longitudinal samples from rejectors, the probability of TCMR increased well 
ahead of rejection and decreased after treatment (Fig. 5a) following kidney 
function and not immunosuppression changes. There was a very clear difference 
between rejectors and non-rejectors at the time of rejection (p<0·0001 for the 
group term in GLMM) and a clear difference between the average trajectories of 
the two groups (Supplementary Fig. S9). Discrimination between rejectors and 
non-rejectors was possible for at least five weeks before and four weeks after 
rejection. AUC remained near or above 0·80 for the five weeks preceding 
rejection and above 0.70 for weeks six and seven (Fig. 5b). It is not a common 
practice in the UK to use anti-thymocyte globuline (ATG) as an induction agent, 
but 11 of the rejectors had received it as a treatment for rejection. The 
probability of TCMR increased before the biopsy and remained above 0.70 
within two weeks after administration of ATG and in some of the patients for 
considerably longer (Supplementary Fig. S10). 
Given the histological similarities between BKVN and TCMR and the fact that 
they both represent some form of inflammation, it was important to explore 
whether the genes in the TCMR signature reflect BKVN activity. To assist 
differential diagnosis, we additionally developed a parsimonious six-gene 
signature of BKVN (Supplementary Fig. S11/S6b/S12, Tables S4/S5), showing 
(like the TCMR signature) an improved performance at cross-validation (CV.AUC 
0·73 (0·66-0·80)) compared to the full 22-gene model (Table 3). Only MARCH8 
and WDR40A genes were shared between the two signatures. These genes were 
strongly positively correlated (r=0·96, p<0·0001 in the joint signature-
development group of rejectors, BKVN, and stable patients), but were lower in 
TCMR compared to BKVN (Supplementary Fig. S7) and were selected by the 
statistical algorithm as informative in both signatures because the signature for 
BKVN was trained to discriminate BKVN from TCMR, as well as from stable 
patients. Correspondingly, the signatures of BKVN and TCMR were negatively 
correlated (r=−0·45, p<0·0001). Notably, the majority of TCMR and mixed-type 
rejectors were BKVN-negative pre-biopsy (Fig. 6a-c). The specificity of the BKVN 
signature in longitudinal samples from stable patients and non-rejectors was 
close or above 70% (Table 4), similarly in Basiliximab and Rituximab-induced 




patients (Fig. 6g), with virtually no double-positives for TCMR and BKVN (Table 
4). On the contrary, 67% of the samples from Alemtuzumab-induced non-
rejectors were BKVN-positive and, as high as 44%, were double-positive, with 
only a few samples being double-negative (Table 4). KTRs pre-transplantation 






We present out the most comprehensive analysis of potential non-invasive 
biomarkers of AR following kidney transplantation to date. Notably, we have 
conducted longitudinal, as well as cross sectional analysis, considering changes 
in gene expression over time post-transplantation. We have also examined the 
effect of immunosuppressive agents (type of induction agent and prednisolone 
reduction) and have shown separation from BKVN, a different form of allograft 
inflammation. We accept, however, that a limitation of our study is the relatively 
small number of independent validation patients with TCMR, the lack of 
diagnostically difficult patients and the very limited number of BKVN patients. It 
should also be noted that AR is not a simplified present/absent condition and has 
various degrees of severity, so the clinical value of AUCs and other performance 
measures for binary outcomes should be evaluated with caution. Further, the 
number of patients with features only of ABMR in the first biopsy diagnostic of 
AR was limited, so we could not reliably evaluate whether our six-gene signature 
could discriminate TCMR from ABMR, or whether it would have the same 
predictive value for ABMR. However, we believe that our signature is relevant to 
TCMR because it includes genes that have been associated with TCMR in 
completely different datasets and the statistical algorithm was trained to 
discriminate TCMR from non-rejection. 
 
Two previous similarly-sized studies have identified gene panels in non-invasive 
samples to detect AR. The assessment of AR in renal transplantation (AART 
study) involved 436 adult renal transplant recipients from eight transplant 
centres in the United States (US), Spain and Mexico and used the 17 gene panel 
kidney solid organ response test (kSORT) to detect patients at high risk of AR.16 
However, this study collected only cross-sectional samples with lower number of 
samples analysed, from a heterogeneous population of both, adult and paediatric 
recipients, from different countries and without a standard immunosuppression 
regimen. Given that the majority of the centres were in the US, it is likely they 
received depleting antibody induction therapy. This might explain why the 
statistical selection of genes for their signature did not favour any of the 
literature-based genes selected by the statistical algorithm in our signature, 
when it is highly likely that the microarrays informing gene selection in the 
AART study would have contained these genes. As some of the genes involved 
are derived from lymphocytes, which are killed by depleting induction therapy, it 
is not surprising that we have found an effect of this therapy on our biomarker 
performance. Potentially, differences in the statistical approaches for selection 
may have also contributed to the lack of overlap. The CTOT-04 study collected 
serial urine samples from 485 recipients from multiple centres across the US, 




and identified a three-gene signature predictive of AR.2 However, the study 
highlighted the difficulty of QC of urine samples. Analysis of urine is not possible 
in many patients with delayed graft function and anuria. This signature was also 
positive in BKVN.  
 
Our study is the only one to date to demonstrate and display the pronounced 
within-patient gene-expression variability, systematic changes post-
transplantation and association with prednisolone dose. It also uniquely 
examines individual patient trajectories. Our QC samples demonstrated very low 
between-batch variability, indicating that the high within-person variability is 
driven by biological, rather than analytical factors. TCMR-positivity in non-
rejectors with poorer kidney function was similar to that in stable KTRs with 
good kidney function (Table 4), illustrating that our TCMR signature provides 
information on the underlying immunological response, independent of kidney 
function. Further, half of the samples from healthy controls, expected to show 
vigilant immunological response to everyday environmental triggers, were 
TCMR-positive, indicating an association of our TCMR signature with active host-
defence mechanisms.  
Evidence that the TCMR signature genes reflect pro-inflammatory 
immunological pathways stems from the fact that IFNG and IP10, both coding 
cytokines generated after Th1-cell activation,17 were up-regulated in TCMR 
(Supplementary Fig. S5). Further, SEMA7A gene, included in the Allomap 
signature of cardiac AR18 and strongly negatively associated with heart 
function,19 showed the highest positive regression coefficient, equivalent to the 
largest fold-increase in TCMR (Supplementary Fig. S5). Its product Sema7A, a 
membrane bound semaphorine, is a potent pro-inflammatory monocyte20 and 
macrophage stimulator.21 
 
Our signature emerges four weeks earlier than that shown by a three-gene urine-
based signature of TCMR,2 which shares with our signature IP10 up-regulation. 
Similarly Perforin, GranzymeB, CXCR3 and TGFB were statistically excluded as not 
relevant to TCMR discrimination (Supplementary Fig. S5). A criticism of the 
three-gene signature has been the lack of discrimination from BKVN.22 We, 
however, additionally provide a six-gene BKVN signature, negatively associated 
with the predicted probability of TCMR, to complement the differential diagnosis 
(Supplementary Fig. S11). Only in the case of Alemtuzumab induction there was 
high positivity for both, TCMR and BKVN (Table4), the latter likely stemming 
from the vigorous immunosuppression. All healthy controls and KTRs pre-
transplantation (Fig. 6d) were strongly BKVN-negative, further supporting that 
our BKVN signature reflects BKV activation kept tightly under control in 
individuals without immunosuppression. 
In support of a mechanistic involvement of BKVN signature-genes 
(Supplementary Fig. S11) in the immune response to viral pathogens, TGFB gene 
expression in peripheral blood mononuclear cells and transplants has been 
found positively associated with BKV viremia and BKVN in KTRs.23-25 Further, 
IL15 gene, the product of which is instrumental to NK-cell activation in response 
to viral infections26 and is implicated in the expansion of BKV-specific T-cells,27 
has been reported as downregulated in human endothelial cells infected with 
BKV.28 In addition, MARCH8, has been identified as an antiviral factor involved in 




reduction of viral infectivity, with high expression in monocyte-derived 
macrophages.29 Nevertheless, our BKVN signature would need further validation 
in a larger BKVN dataset. 
 
While not able to replace the present biopsies as a gold standard to confirm AR, 
our panel may have a role in serial monitoring, providing the clinician with 
valuable extra information on immune system status to help manage KTRs. Serial 
monitoring with biopsies remains a high-risk, costly and impractical strategy. 
Clinical decision-making post-transplantation is complex and utilises a number 
of factors to determine a particular course of action, and this should remain the 
case. Potential clinical applications of our test  could refine better the patients 
that may need a biopsy, it could include earlier detection and treatment of AR 
through earlier biopsy, help in interpretation of cases where the biopsy is 
reported as “borderline”, detection of sub-clinical rejection in a biopsy where 
there is no evidence of graft dysfunction based on SCr and separation of other 
causes of graft dysfunction such as BKVN. The panel could also be used to detect 
patients at low risk of rejection, thereby allowing reduction of 
immunosuppression, thus minimising side effects. Further prospective analysis 
is now required to determine whether or not the use of such a test can improve 
clinical outcomes.  
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